Healthcare > Pharmaceuticals & Biotechnology
•770 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (770)
%
| Company | Market Cap | Price |
|---|---|---|
|
Direct product category: Arrowhead's core TRiM RNAi therapeutics platform and pipeline drive its value.
|
$4.89B |
$35.41
-1.64%
|
|
Glaukos directly develops and sells ophthalmic drugs (iDose TR, Photrexa, Epioxa) for glaucoma and corneal health, representing core pharmaceutical offerings.
|
$4.72B |
$82.56
-5.10%
|
|
Core oncology biotechnology company focused on multispecific antibody therapeutics (BIZENGRI and petosemtamab) used for cancer.
|
$4.71B |
$69.05
+1.40%
|
|
Directly develops cell therapies (CAR-T) and related platforms (ddCAR, ARC-SparX), which are Arcellx's core product offerings.
|
$4.52B |
$82.10
+3.69%
|
|
Pharmaceuticals & Biotechnology focus (Qsiva product) within the Pharma segment.
|
$4.48B |
$8.28
+1.10%
|
|
Directly tied to Akero's lead product candidate EFX being developed as a ready-to-use pre-filled syringe formulation for administration.
|
$4.30B |
$53.88
-0.39%
|
|
The company develops oral, nonpeptide small molecule therapeutics (e.g., paltusotine) for endocrine GPCR targets.
|
$4.08B |
$42.32
-2.74%
|
|
Oral small molecule therapeutics: Kymera aims to deliver biologics-like efficacy with oral dosing, representing a major product class.
|
$4.00B |
$56.00
+1.49%
|
|
VK2735 is a peptide-based therapeutic (dual GLP-1/GIP receptor agonist), placing it squarely in the Peptide Therapeutics category.
|
$3.77B |
$33.56
-6.13%
|
|
SMA is a rare disease and Scholar Rock's lead program apitegromab targets this indication.
|
$3.75B |
$39.46
-3.94%
|
|
Radium radiopharmaceutical isotopes development (TAT) using Mill streams; potential commercial isotope production.
|
$3.74B |
$16.71
-4.57%
|
|
ADMA's core offerings are plasma-derived immunoglobulin therapies (ASCENIV, BIVIGAM, Nabi-HB) for immune deficiencies, aligning with Immunology Therapeutics.
|
$3.73B |
$15.61
+1.17%
|
|
Pipeline includes radioligand therapy/theranostic assets; radiopharmaceutical therapy is a key investable theme for the company.
|
$3.68B |
$53.23
+2.54%
|
|
Mirum's core business is focused on rare diseases with approved medicines and a pipeline targeting orphan conditions (CTX, PFIC/ALGS, PSC/PBC).
|
$3.64B |
$73.57
-0.65%
|
|
Integer is a contract development and manufacturing organization for medical devices, providing outsourced development and manufacturing services to OEMs.
|
$3.53B |
$101.05
-1.93%
|
|
ACADIA develops CNS/neuropsychiatric therapeutics, including NUPLAZID for PDP and DAYBUE for Rett syndrome, positioning it in neuropsychiatric drug development.
|
$3.52B |
$21.05
-0.94%
|
|
Oral Small Molecule Therapeutics: SpringWorks' approved assets OGSIVEO and GOMEKLI are oral, small-molecule targeted therapies forming the core revenue streams.
|
$3.52B |
$46.99
|
|
Biotech - Rare Diseases: company focusing on rare disease diagnostics and data assets.
|
$3.47B |
$121.72
-4.53%
|
|
Zai Lab's portfolio and late-stage pipeline are heavily oncology-focused with potential blockbusters and China/global development.
|
$3.43B |
$31.62
+0.86%
|
|
Ligand's Captisol and NITRICIL platforms are proprietary drug-delivery technologies that Ligand licenses to partners, representing a direct product/platform offering.
|
$3.43B |
$177.73
-2.16%
|
|
Obicetrapib is an oral small-molecule therapeutic candidate developed by NewAmsterdam Pharma, representing the core product category.
|
$3.42B |
$37.05
+10.86%
|
|
Telix's core offering includes radioligand therapies using radiopharmaceuticals for cancer (alpha-emitter and related therapies).
|
$3.35B |
$10.00
|
|
Directly develops oncology-focused biologic/cancer therapy (cretostimogene) used to treat bladder cancer.
|
$3.30B |
$43.25
-3.74%
|
|
Indivior is a global pharmaceutical company with core revenue from SUBLOCADE and related OUD therapies, fitting the Large Cap Pharma category.
|
$3.28B |
$23.78
-1.53%
|
|
Soleno's VYKAT XR is an oral small-molecule therapeutic targeted at hyperphagia in Prader-Willi Syndrome.
|
$3.27B |
$62.72
-1.74%
|
|
HUTCHMED directly develops and sells oral, small-molecule targeted therapeutics across oncology and immunology indications.
|
$3.15B |
$3.66
|
|
Core business: Amneal's primary revenue driver is generic medicine manufacturing (Affordable Medicines).
|
$3.12B |
$9.97
-3.11%
|
|
Xenon’s portfolio centers on oral small‑molecule CNS therapeutics (Kv7 opener XEN1101 and related programs) with epilepsy and neuropsychiatric expansion.
|
$3.04B |
$39.64
-4.34%
|
|
PBH's flagship eye-care products (e.g., Clear Eyes) are ophthalmic drugs, making Ophthalmic Drugs a direct product category.
|
$3.01B |
$61.00
-2.80%
|
|
uniQure directly develops AAV-based gene therapies and its proprietary miQURE silencing technology, which are the core products/services it provides.
|
$3.01B |
$54.50
-2.45%
|
|
The company’s infusion-pump platform (Plum Duo/Solo/360) and related delivery technology fit the Drug Delivery Platforms category.
|
$3.01B |
$119.67
-0.24%
|
|
Centessa is advancing oncology-focused therapies via the LockBody platform.
|
$2.98B |
$22.31
-2.75%
|
|
Directly develops and commercializes gene therapies using AAV vectors for rare diseases, covering programs like UX111, DTX401, UX701, UX143, and GTX-102.
|
$2.97B |
$31.45
-1.13%
|
|
XDEMVY is an ophthalmic drug (lotilaner ophthalmic solution 0.25%) and the company's flagship product, establishing a major ophthalmic drug category.
|
$2.95B |
$70.14
-0.09%
|
|
NiQuitin is an OTC nicotine replacement therapy product within Perrigo's portfolio.
|
$2.92B |
$21.25
-1.67%
|
|
SYFOVRE is an ophthalmic drug (intravitreal pegcetacoplan) approved for geographic atrophy, representing the company's core marketed product.
|
$2.86B |
$22.76
-1.85%
|
|
Immunology therapeutics focus: ARCALYST and pipeline IL-1 pathway inhibitors place Kiniksa in the immunology/anti-inflammatory therapeutics space.
|
$2.76B |
$37.89
-0.58%
|
|
Ascentage Pharma’s core business is oncology-focused biotechnology with approved and pipeline small-molecule cancer therapies (olverembatinib, lisaftoclax, alrizomadlin).
|
$2.75B |
$34.94
-5.05%
|
|
Lorundrostat is an orally administered, small-molecule therapeutic, aligning Mineralys with the 'Oral Small Molecule Therapeutics' category.
|
$2.75B |
$42.16
+6.98%
|
|
Organon's Hadlima, Renflexis, and Ontruzant biosimilars are core revenue drivers.
|
$2.75B |
$10.65
+0.80%
|
|
IMVT-1402 is a monoclonal antibody therapeutic targeting FcRn, central to Immunovant's drug platform.
|
$2.75B |
$16.07
-0.77%
|
|
Core CNS neuropsychiatric drug development focus aligns with Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE and the pipeline assets.
|
$2.74B |
$49.00
-0.79%
|
|
Companion diagnostics-style biomarker tests that identify patients most likely to respond to specific therapies.
|
$2.73B |
$34.80
-0.66%
|
|
Directly develops and commercializes allogeneic mesenchymal stromal cell therapies (RYONCIL and rexlemestrocel-L).
|
$2.72B |
$2.12
|
|
Beam Therapeutics is built around a gene therapy platform (base editing) and develops therapeutic programs that edit genes to treat diseases.
|
$2.65B |
$26.32
-7.58%
|
|
Core business focus on rare-disease therapies (Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease) sold/commercialized directly.
|
$2.56B |
$8.30
|
|
Company develops oral small-molecule therapeutics (bitopertin and DISC pipeline), a major product category in pharma.
|
$2.42B |
$69.90
-0.87%
|
|
Lead product ANKTIVA is an oncology immunotherapy (cytokine fusion protein) and core revenue driver.
|
$2.40B |
$2.54
+0.20%
|
|
ARQT's ZORYVE is a non-steroidal topical immunomodulatory therapy for inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$2.39B |
$20.05
-3.28%
|
|
Focus on cancer detection/diagnostics places GRAIL in Biotech - Oncology category.
|
$2.38B |
$66.13
-7.38%
|
|
Company develops immunology-focused biologics (antibodies) for inflammatory and immune-mediated diseases.
|
$2.37B |
$39.88
-0.18%
|
|
Agios' lead product mitapivat and pipeline tebapivat are oral small‑molecule therapeutics for rare hematologic diseases.
|
$2.35B |
$40.61
-4.47%
|
|
Catalyst's core business is developing and commercializing rare-disease therapies (FIRDAPSE, AGAMREE, FYCOMPA), aligning with Biotech - Rare Diseases.
|
$2.33B |
$19.13
-2.60%
|
|
Tinlarebant is a lead oral small-molecule therapeutic (LBS-008) targeting retinal diseases.
|
$2.31B |
$79.28
+1.03%
|
|
IDEAYA develops targeted cancer therapies and biomarker-driven precision oncology platforms, fitting Biotech - Oncology.
|
$2.30B |
$26.24
-2.42%
|
|
Galapagos is pivoting to and actively developing cell therapies (CAR-T) for oncology, which is the core product focus.
|
$2.25B |
$34.10
+0.86%
|
|
Company is a large-cap pharmaceutical with a diversified portfolio and core revenue from prescription medicines and ophthalmic products.
|
$2.24B |
$6.05
-4.87%
|
|
Denali's TransportVehicle (TV) platform is a proprietary drug delivery platform designed to cross the blood-brain barrier, representing a major Drug Delivery Platforms investable theme.
|
$2.23B |
$15.37
-5.12%
|
|
Travere's lead product FILSPARI (sparsentan) targets rare kidney diseases (IgA nephropathy) and is the core commercial/late-stage product, classed under Rare Diseases.
|
$2.21B |
$24.85
+2.10%
|
|
Directly develops and commercializes gene therapies (ELEVIDYS) and gene-targeted modalities; core product category in Sarepta's business.
|
$2.17B |
$22.11
-4.49%
|
|
Direct product category: Mesoblast's core offering is allogeneic mesenchymal lineage cell therapies (Ryoncil, rexlemestrocel-L, Revascor), which fit 'Biotech - Cell Therapy'.
|
$2.11B |
$18.32
-4.03%
|
|
Company's core oncology MRD diagnostics (clonoSEQ) and immune medicine platform target cancer monitoring and treatment.
|
$2.03B |
$13.36
-3.68%
|
|
Strategic focus on oncology programs within the biotech/pharmaceutical pipeline (precision oncology).
|
$2.02B |
$4.81
-3.99%
|
|
Generic Drugs is a core revenue driver for ANI with multiple new product launches and CGT-related exclusivity driving the Generics & Other segment.
|
$1.99B |
$90.17
-1.51%
|
|
YUTREPIA and Liquidia's cardiovascular prostacyclin program place the company in the Cardiovascular Drugs category.
|
$1.98B |
$23.19
-5.19%
|
|
ELUTYX is a proprietary drug-delivery platform powering sustained release, underpinning AXPAXLI, a core retinal program.
|
$1.94B |
$12.48
+1.88%
|
|
Antibody libraries for drug discovery reflect an antibody discovery platform offering.
|
$1.87B |
$31.19
-6.39%
|
|
Lead asset bezuclastinib is an oral small-molecule tyrosine kinase inhibitor targeting KIT D816V, aligning with the Oral Small Molecule Therapeutics category.
|
$1.85B |
$16.27
|
|
Gedatolisib is a pan-PI3K/mTOR inhibitor targeting oncology indications, aligning with Biotech - Oncology as the direct product category.
|
$1.74B |
$46.07
-6.25%
|
|
Celldex's lead product barzolvolimab is a humanized monoclonal antibody targeting KIT, a core monoclonal antibody therapeutic.
|
$1.74B |
$26.14
+1.79%
|
|
KIMMTRAK is a leading oncology therapy (metastatic uveal melanoma) and Immunocore is expanding an ImmunTAX-based oncology pipeline, making Biotech - Oncology the core investable theme.
|
$1.72B |
$34.27
-0.95%
|
|
Viridian's lead assets are monoclonal antibodies (veligrotug and VRDN-003), placing the company in Monoclonal Antibody Therapeutics.
|
$1.71B |
$20.99
-3.94%
|
|
Intellia's core offerings are in vivo CRISPR gene therapy programs, representing Biotech - Gene Therapy.
|
$1.69B |
$16.31
-1.33%
|
|
Directly developing immunology therapeutics with atacicept (dual BAFF/APRIL inhibitor) for autoimmune diseases.
|
$1.67B |
$26.14
-0.04%
|
|
STOKE is targeting rare genetic diseases (haploinsufficiency) with lead programs for Dravet syndrome and ADOA, a core Rare Diseases focus.
|
$1.65B |
$30.19
-2.46%
|
|
Directly applies to Kv7 ion channel modulation and TRPM3 antagonism platforms powering CNS, pain, and neuroimmune programs.
|
$1.61B |
$15.80
-9.97%
|
|
Core product category: oral small molecule therapeutics.
|
$1.61B |
$28.00
+10.54%
|
|
Vericel's core products are autologous cell therapies (MACI, Epicel) and related biologic offerings, making 'Biotech - Cell Therapy' a direct representation of their primary manufacturing focus.
|
$1.60B |
$31.85
-3.51%
|
|
FORCE platform enables targeted delivery of genetic payloads to muscle/CNS, making Dyne a direct developer of gene therapy–like therapeutics.
|
$1.60B |
$14.05
-0.57%
|
|
Edgewise's core offerings are orally administered small-molecule therapeutics (sevasemten, EDG-7500).
|
$1.59B |
$15.11
-5.92%
|
|
Direct product: vaccines for animal health as part of Phibro's Animal Health segment.
|
$1.57B |
$38.04
+0.34%
|
|
Arcus Biosciences operates as a oncology-focused biotech developing cancer therapies (HIF-2α inhibitor casdatifan and IO antibodies).
|
$1.55B |
$14.60
-4.20%
|
|
LUPKYNIS is an oral small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$1.53B |
$11.35
+0.44%
|
|
Harmony's pipeline centers on oral small molecule CNS therapies (narcolepsy/EDS, rare neuropsychiatric indications) and WAKIX is an oral small molecule; multiple assets in development follow this format.
|
$1.52B |
$26.54
-1.19%
|
|
ORLADEYO is BioCryst's flagship oral small-molecule therapeutic for hereditary angioedema, forming the core product and revenue driver.
|
$1.51B |
$7.22
-0.48%
|
|
Avadel directly markets LUMRYZ, an oral small-molecule therapeutic for narcolepsy.
|
$1.51B |
$15.49
-0.61%
|
|
NovoCure's TTFields oncology therapy platform is used to treat multiple cancer indications, aligning with Oncology-focused biotech/device ecosystems.
|
$1.50B |
$13.49
-5.99%
|
|
The Cloudbreak platform represents a drug delivery platform technology (Drug Delivery Platforms) used to create Drug-Fc Conjugates with extended half-life for therapeutics.
|
$1.47B |
$113.05
-2.88%
|
|
AbCellera's differentiated AI-powered platform is the core product enabling discovery of antibodies, including GPCRs/ion channels and T-cell engager platforms.
|
$1.45B |
$5.03
+2.86%
|
|
Core focus on oncology therapeutics (tumor-activated immunotherapies) under Biotech - Oncology.
|
$1.45B |
$24.44
+3.25%
|
|
Novavax directly develops and commercializes vaccines (e.g., Nuvaxovid) and licenses its Matrix-M adjuvant/platform, making 'Vaccines' the primary investable product category.
|
$1.38B |
$8.55
+2.64%
|
|
Revuforj is an oral small-molecule therapeutic (menin inhibitor), aligning with 'Oral Small Molecule Therapeutics'.
|
$1.38B |
$16.06
-1.35%
|
|
Evotec provides outsourced drug discovery and preclinical development services as a CRO.
|
$1.38B |
$7.28
|
|
Harrow directly develops and sells ophthalmic drugs (VEVYE, IHEEZO, TRIESENCE, BYQLOVI) and biosimilars in the ophthalmic space, i.e., ophthalmic drugs.
|
$1.38B |
$37.48
-8.02%
|
|
Company develops small-molecule oral CFTR modulators (SION-719, SION-451) targeting CF; a core oral small molecule therapeutics product category.
|
$1.32B |
$29.93
-0.28%
|
|
Xeris Biopharma is a pharmaceutical company commercializing drugs (Recorlev, Gvoke, Keveyis), fitting the Large Cap Pharma category.
|
$1.28B |
$7.99
-2.44%
|
|
Nuvation Bio is developing oncology therapies (IBTROZI and Safusidenib) and has a pipeline focused on cancer indications.
|
$1.27B |
$3.74
-1.84%
|
|
PBH and Wolfram PSP represent rare diseases addressed by Amylyx's pipeline, aligning with the Biotech - Rare Diseases theme.
|
$1.27B |
$14.26
-1.11%
|
|
Zymeworks directly develops and licenses Antibody-Drug Conjugates (ADCs), including zanidatamab and WHOLLY-OWNED ADCs like ZW191, ZW251, and ZW220.
|
$1.26B |
$18.06
+4.39%
|
|
Lead asset pacibetKITug is a fully human monoclonal antibody targeting IL-6, placing Tourmaline Bio in immunology therapeutics.
|
$1.23B |
$47.75
|
Showing page 2 of 8 (770 total stocks)
Loading industry metrics...
Loading comparison data...
